What BioGeometry does
BioGeometry, founded in Beijing in 2022 by Prof. Jian Tang with Turing Award laureate Yoshua Bengio as chief scientific advisor, and operating an additional R&D center in Shanghai, builds GeoFlow, a generative AI model unifying sequence, structure and function prediction for proteins. The company applies GeoFlow to epitope-specific antibody design for drug development and to enzyme design for sustainable bio-manufacturing, and it has a strategic partnership with Sino Biological to supply AI-enabled protein R&D services. GeoFlow V2 was among the first models worldwide to unify structure prediction and de novo protein design in one system, and a hosted demo is available at prot.design. The company's own newsroom reports it closed a strategic financing round of 'hundreds of millions' of RMB, announced June 30 2026, led by Shanghai Healthcare Angel Capital, CAS Investment Management, Fortune Capital and Star Chain Capital.
BioGeometry is a healthcare tool on Falcoscan. Generative AI that designs antibodies and enzymes from scratch. Falcoscan rates BioGeometry with an Opportunity score of 86/100, a Saturation score of 11/100, and a Wrapper-risk score of 9/100. Market signal: hot. BioGeometry is founded in 2022, currently at Series_b stage. Pricing: Paid.